Squarepoint’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.24M | Sell |
15,426
-39
| -0.3% | -$3.21K | ﹤0.01% | 2595 |
|
|
2025
Q4 | $1.32M | Sell |
15,465
-211,661
| -93% | -$17.4M | ﹤0.01% | 2380 |
|
|
2025
Q3 | $17.7M | Buy |
227,126
+157,863
| +228% | +$12.3M | 0.02% | 804 |
|
|
2025
Q2 | $5.42M | Buy |
69,263
+53,424
| +337% | +$3.98M | 0.01% | 1407 |
|
|
2025
Q1 | $1.15M | Sell |
15,839
-52,321
| -77% | -$3.74M | ﹤0.01% | 2542 |
|
|
2024
Q4 | $5.05M | Sell |
68,160
-621,276
| -90% | -$43.5M | 0.01% | 1624 |
|
|
2024
Q3 | $45.5M | Buy |
689,436
+665,713
| +2,806% | +$48.4M | 0.07% | 263 |
|
|
2024
Q2 | $2.19M | Sell |
23,723
-8,173
| -26% | -$724K | ﹤0.01% | 1984 |
|
|
2024
Q1 | $3.05M | Sell |
31,896
-437,542
| -93% | -$36.8M | 0.01% | 1812 |
|
|
2023
Q4 | $35.8M | Buy |
469,438
+300,949
| +179% | +$20.9M | 0.07% | 319 |
|
|
2023
Q3 | $11.7M | Buy |
168,489
+145,258
| +625% | +$11.7M | 0.03% | 730 |
|
|
2023
Q2 | $2.19M | Sell |
23,231
-86,496
| -79% | -$7.52M | 0.01% | 1605 |
|
|
2023
Q1 | $9.08M | Sell |
109,727
-763,992
| -87% | -$60.1M | 0.04% | 597 |
|
|
2022
Q4 | $65.2M | Buy |
873,719
+689,415
| +374% | +$53.1M | 0.26% | 61 |
|
|
2022
Q3 | $15.2M | Buy |
184,304
+103,824
| +129% | +$9.99M | 0.08% | 291 |
|
|
2022
Q2 | $7.65M | Sell |
80,480
-68,315
| -46% | -$7.07M | 0.04% | 492 |
|
|
2022
Q1 | $17.5M | Buy |
148,795
+8,735
| +6% | +$980K | 0.07% | 278 |
|
|
2021
Q4 | $18.1M | Buy |
140,060
+116,170
| +486% | +$13.6M | 0.05% | 331 |
|
|
2021
Q3 | $2.71M | Sell |
23,890
-75,741
| -76% | -$8.65M | 0.01% | 1056 |
|
|
2021
Q2 | $10.3M | Buy |
+99,631
| New | +$9.39M | 0.04% | 452 |
|
|
2021
Q1 | – | Sell |
-16,336
| Closed | -$1.38M | – | 3254 |
|
|
2020
Q4 | $1.49M | Buy |
+16,336
| New | +$1.36M | 0.01% | 1094 |
|
|
2020
Q3 | – | Sell |
-256,741
| Closed | -$17.7M | – | 2574 |
|
|
2020
Q2 | $17.7M | Buy |
256,741
+207,202
| +418% | +$14.7M | 0.29% | 66 |
|
|
2020
Q1 | $3.12M | Sell |
49,539
-222,726
| -82% | -$16.1M | 0.08% | 315 |
|
|
2019
Q4 | $21.2M | Buy |
272,265
+195,561
| +255% | +$15.3M | 0.13% | 134 |
|
|
2019
Q3 | $5.62M | Sell |
76,704
-335,787
| -81% | -$23.6M | 0.05% | 445 |
|
|
2019
Q2 | $25.4M | Buy |
+412,491
| New | +$24.9M | 0.25% | 91 |
|
|
2019
Q1 | – | Sell |
-33,222
| Closed | -$1.7M | – | 2227 |
|
|
2018
Q4 | $1.7M | Buy |
33,222
+26,622
| +403% | +$1.35M | 0.02% | 730 |
|
|
2018
Q3 | $383K | Buy |
+6,600
| New | +$323K | ﹤0.01% | 1430 |
|
|
2018
Q1 | – | Sell |
-227,574
| Closed | -$8.55M | – | 1812 |
|
|
2017
Q4 | $8.55M | Sell |
227,574
-284,379
| -56% | -$10.4M | 0.15% | 152 |
|
|
2017
Q3 | $18.7M | Buy |
511,953
+450,738
| +736% | +$17.2M | 0.36% | 61 |
|
|
2017
Q2 | $2.41M | Sell |
61,215
-73,188
| -54% | -$2.67M | 0.05% | 464 |
|
|
2017
Q1 | $4.21M | Buy |
+134,403
| New | +$4.21M | 0.12% | 217 |
|
|
2016
Q3 | – | Sell |
-110,427
| Closed | -$3.67M | – | 1079 |
|
|
2016
Q2 | $3.67M | Buy |
110,427
+59,430
| +117% | +$2.03M | 0.23% | 89 |
|
|
2016
Q1 | $1.5M | Sell |
50,997
-54,366
| -52% | -$1.5M | 0.12% | 245 |
|
|
2015
Q4 | $2.77M | Buy |
+105,363
| New | +$2.74M | 0.3% | 44 |
|
|
2015
Q1 | – | Sell |
-34,800
| Closed | -$739K | – | 444 |
|
|
2014
Q4 | $739K | Buy |
+34,800
| New | +$699K | 0.72% | 43 |
|
Other funds holding EW
VCM
VPM
Squarepoint's EW Position: Q1 2026 in Review
Squarepoint reduced its Edwards Lifesciences (EW) stake by 0.25% in Q1 2026, selling an estimated $3.21K and leaving 15,426 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2595.
Squarepoint first reported a position in EW in Q4 2014 and has held it in 36 quarters since. The position peaked at $65.2M in Q4 2022. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Squarepoint held 15,426 shares of Edwards Lifesciences worth $1.24M as of Q1 2026.
- Squarepoint sold 39 Edwards Lifesciences shares in Q1 2026, an estimated $3.21K.
- Edwards Lifesciences made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2595 holding.
- Squarepoint first reported a position in Edwards Lifesciences in Q4 2014 and has held it in 36 quarters since.
- Squarepoint's Edwards Lifesciences position peaked at $65.2M in Q4 2022.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.